Promigratory and procontractile growth factor environments differentially regulate cell morphogenesis.
Three-dimensional (3D) cell-matrix cultures provide a useful model to analyze and dissect the structural, functional, and mechanical aspects of cell-matrix interactions and motile behavior important for cell and tissue morphogenesis. In the current studies we tested the effects of serum and physiological growth factors on the morphogenetic behavior of human fibroblasts cultured on the surfaces of 3D collagen matrices. Fibroblasts in medium containing serum contracted into clusters, whereas cells in medium containing platelet-derived growth factor (PDGF) were observed to migrate as individuals. The clustering activity of serum appeared to depend on lysophosphatidic acid, required cell contraction based on inhibition by blocking Rho kinase or myosin II, and was reversed upon switching to PDGF. Oncogenic Ras transformed human fibroblasts did not exhibit serum-stimulated cell clustering. Our findings emphasize the importance of cell-specific promigratory and procontractile growth factor environments in the differential regulation of cell motile function and cell morphogenesis.
Rhee
Sangmyung
S
Department of Life Science, Chung-Ang University, Seoul, South Korea.
Ho
Chin-Han
CH
Grinnell
Frederick
F
D000199:Actins / Q000378:metabolism; D000577:Amides / Q000494:pharmacology; D002449:Cell Aggregation / Q000187:drug effects / Q000502:physiology*; D018929:Cell Culture Techniques; D002461:Cell Line, Transformed; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D048430:Cell Shape / Q000187:drug effects / Q000502:physiology*; D003094:Collagen / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology / Q000502:physiology*; D008246:Lysophospholipids / Q000172:deficiency / Q000494:pharmacology; D008297:Male; D024462:Myosin Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D015689:Oncogene Protein p21(ras) / Q000235:genetics; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D044967:Serum / Q000502:physiology; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D016596:Vinculin / Q000378:metabolism; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000199:Actins; D000577:Amides; D004791:Enzyme Inhibitors; D006576:Heterocyclic Compounds, 4 or More Rings; D036341:Intercellular Signaling Peptides and Proteins; D008246:Lysophospholipids; D010982:Platelet-Derived Growth Factor; D011725:Pyridines; D016596:Vinculin; C108830:Y 27632; C472645:blebbistatin; C060506:sphingosine 1-phosphate; D003094:Collagen; D054460:rho-Associated Kinases; D024462:Myosin Type II; D015689:Oncogene Protein p21(ras); D013110:Sphingosine; C032881:lysophosphatidic acid